Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.48 |
| ▸ | CPT2 | P23786 | 1/20 | 0.45 |
| ▸ | CPT1A | P50416 | 1/20 | 0.45 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167401 | 0.87 | ROCK2 (0.46) | ROCK2CPT2CPT1A | |
| SCHEMBL164861 | 0.84 | POLB (0.53) | ROCK2HSP90AA1HSP90AB1RHOAMEN1 | |
| SCHEMBL166794 | 0.81 | ROCK2 (0.60) | ROCK2HSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL165849 | 0.81 | ROCK2 (0.49) | ROCK2HSP90AA1HSP90AB1CPT2CPT1A | |
| SCHEMBL165848 | 0.81 | ROCK2 (0.49) | ROCK2HSP90AA1HSP90AB1CPT2CPT1A | |
| SCHEMBL169074 | 0.80 | ROCK2 (0.58) | ROCK2HSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL20826492 | 0.78 | KMT2A (0.58) | ROCK2RHOAMEN1ALDH1A1KMT2A | |
| SCHEMBL13753514 | 0.78 | KMT2A (0.58) | ROCK2RHOAMEN1ALDH1A1KMT2A | |
| SCHEMBL165106 | 0.78 | ROCK2 (0.50) | ROCK2HSP90AA1HSP90AB1RHOA | |
| SCHEMBL174578 | 0.77 | GRM5 (0.56) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | ROCK2 1674/4885HSP90AA1 3048/4885HSP90AB1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.